Comparisons

Zepbound vs Wegovy in 2026: Updated Head-to-Head Comparison

GLP-1 Companion · 9 min read

For years, patients and clinicians asked the same question: Zepbound or Wegovy? The drugs were compared only indirectly through separate trials in different populations. That changed with the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025 — the first large, randomized, head-to-head comparison of tirzepatide (Zepbound) and semaglutide (Wegovy) for weight management. Combined with the evolving landscape of FDA approvals, insurance coverage, and real-world experience, the evidence in 2026 offers a clearer picture than ever of how these two medications compare and who is best served by each.

SURMOUNT-5: The Head-to-Head Trial That Changed the Conversation

SURMOUNT-5 enrolled adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity, without type 2 diabetes. Participants were randomized to tirzepatide (escalated to maximum tolerated dose up to 15 mg weekly) or semaglutide 2.4 mg weekly (Wegovy) for 72 weeks. The results, published in the New England Journal of Medicine in early 2025, showed:

• Tirzepatide: 20.2% mean body weight reduction at 72 weeks
• Semaglutide: 13.7% mean body weight reduction at 72 weeks
• Absolute weight loss: 22.8 kg (tirzepatide) vs 15.0 kg (semaglutide)
• Weight loss difference: 6.5 percentage points in favor of tirzepatide
• GI discontinuation rates: 2.7% for tirzepatide vs 5.6% for semaglutide due to GI side effects

Understanding the Efficacy Difference

The efficacy advantage of tirzepatide over semaglutide can be attributed to its dual mechanism of action. While semaglutide is a selective GLP-1 receptor agonist, tirzepatide acts on both the GLP-1 receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. GIP receptor activation appears to amplify the weight loss effect of GLP-1 receptor agonism through multiple pathways, including direct hypothalamic effects, enhanced adipose tissue lipolysis, and potential modulation of energy expenditure. The net result, demonstrated consistently from SURMOUNT-1 through SURMOUNT-5, is meaningfully greater weight loss with tirzepatide than semaglutide at comparable doses.

It is important to note that not all patients respond equally to either drug. Individual response to GLP-1 medications shows substantial variability, and some patients achieve exceptional results with semaglutide while being average responders to tirzepatide. SURMOUNT-5 reports population means; in clinical practice, response must be assessed individually.

GI Side Effect Profile: A Surprising Finding

One of the most clinically relevant findings from SURMOUNT-5 was the tolerability data. Tirzepatide — often expected by clinicians to have worse GI side effects due to its dual mechanism — actually had a lower rate of treatment discontinuation due to GI adverse events: 2.7% for tirzepatide versus 5.6% for semaglutide. Both groups had similar rates of any GI symptom (nausea, vomiting, diarrhea, constipation), but the severity sufficient to cause discontinuation was lower with tirzepatide.

This finding is consistent with earlier SURMOUNT and SURPASS data and may reflect tirzepatide's different dose escalation schedule and receptor pharmacology. For patients who previously stopped semaglutide due to GI intolerance, tirzepatide represents a potentially more tolerable alternative, and many patients in clinical practice have successfully transitioned from semaglutide to tirzepatide for this reason.

Cardiovascular Indication: Wegovy's Current Advantage

As of 2026, semaglutide (Wegovy) holds a broader cardiovascular indication than tirzepatide. The SELECT trial, published in 2023, demonstrated that Wegovy reduces major adverse cardiovascular events (MACE) — including heart attack, stroke, and cardiovascular death — by 20% in patients with established cardiovascular disease and obesity, without type 2 diabetes. Based on this data, the FDA approved Wegovy for the reduction of cardiovascular risk in this patient population in 2024.

Tirzepatide has a dedicated cardiovascular outcomes trial underway (SURPASS-CVOT and SURMOUNT-MMO), but results are not yet fully published as of 2026. For patients whose primary treatment goal is cardiovascular risk reduction alongside weight management, Wegovy currently holds the edge with a formally approved cardiovascular indication. This is a meaningful clinical distinction for cardiologists and primary care physicians prescribing for high-risk cardiovascular patients.

Obstructive Sleep Apnea: Zepbound's Unique Approval

Zepbound (tirzepatide) received FDA approval in 2024 for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity — the first pharmacological treatment approved specifically for this indication. The SURMOUNT-OSA trials demonstrated that tirzepatide reduced the apnea-hypopnea index (AHI) by approximately 63% in patients not using CPAP and approximately 50% in CPAP users, with nearly half of tirzepatide patients achieving disease resolution. This indication is specific to Zepbound and is not currently shared by Wegovy, giving tirzepatide a unique clinical advantage for the substantial population with obesity-related OSA.

Cost Parity and Insurance Coverage in 2026

As of 2026, list prices for Zepbound and Wegovy are roughly comparable, both in the range of $900 to $1,300 per month without insurance coverage. Eli Lilly and Novo Nordisk both offer savings programs and direct-to-consumer pricing options that reduce costs for qualifying patients. The availability of compounded semaglutide and tirzepatide through FDA-registered compounding pharmacies — which peaked in 2024 when both drugs were on the shortage list — has been significantly curtailed following removal of both drugs from the FDA shortage list. Cost differences between the two products have narrowed substantially compared to 2023 and 2024.

Insurance coverage remains the dominant cost driver. Employer-sponsored health plans vary widely in their formulary inclusion of GLP-1 weight loss medications. Medicare continues to cover GLP-1s for type 2 diabetes (Ozempic, Mounjaro) but as of early 2026, coverage for the weight management indications (Wegovy, Zepbound) under Part D remains variable and is the subject of ongoing policy discussion. Patients should verify their specific plan coverage for each drug, as formulary placement differs between Wegovy and Zepbound on many plans.

Who Should Choose Zepbound

• Patients prioritizing maximum weight loss efficacy based on SURMOUNT-5 data.
• Patients with obesity-related obstructive sleep apnea seeking the dedicated OSA indication.
• Patients who previously stopped semaglutide due to GI intolerance.
• Patients with type 2 diabetes seeking both glucose control and weight loss (Mounjaro, tirzepatide's diabetes formulation).
• Patients for whom their insurance plan has better coverage or lower copay for Zepbound.

Who Should Choose Wegovy

• Patients with established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease) who qualify for Wegovy's SELECT-based cardiovascular risk reduction indication.
• Patients whose cardiologist is prescribing specifically for cardiovascular risk reduction rather than weight loss alone.
• Patients whose insurance plan covers Wegovy but not Zepbound, or provides meaningfully lower cost-sharing for Wegovy.
• Patients who have achieved excellent results with semaglutide in the past and prefer to restart a familiar medication.
• Patients for whom injection volume or device design preference favors the Wegovy auto-injector.

SURMOUNT-5 establishes tirzepatide as the more efficacious weight loss agent in a direct comparison. But efficacy is only one variable. Cardiovascular indication, OSA approval, tolerability, insurance coverage, and individual patient history all matter in the real-world choice between Zepbound and Wegovy.

2026 Comparison Summary

• Weight loss at 72 weeks (SURMOUNT-5): Zepbound 20.2% vs Wegovy 13.7%
• Absolute weight loss: 22.8 kg (Zepbound) vs 15.0 kg (Wegovy)
• GI discontinuation rate: 2.7% (Zepbound) vs 5.6% (Wegovy)
• Cardiovascular risk reduction approval: Wegovy only (SELECT data, 20% MACE reduction)
• Obstructive sleep apnea approval: Zepbound only (SURMOUNT-OSA data)
• Mechanism: Zepbound dual GIP+GLP-1 agonist; Wegovy selective GLP-1 agonist
• Cost parity: broadly similar list prices in 2026; insurance formulary placement varies

Sources

• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.
• Jastreboff et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. NEJM.